




an Open Access Journal by MDPI

Impact Factor 3.9

CiteScore 6.8

Indexed in PubMed

Biomedicines



[mdpi.com/
journal/
biomedicines](https://mdpi.com/journal/biomedicines)



Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, biosimilar, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, biosimilars, and nano-biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

Section Editors-in-Chief

Dr. Veronique Baud

Dr. Timo Gaber

Dr. Bernard Lebleu

Prof. Dr. Jun Lu

Dr. Bruno Meloni

Prof. Dr. Stephen Riordan

Prof. Dr. Paul Rösch

Aims

Biomedicines publishes high-quality papers that address the challenges in bringing biological agents or novel targeted strategies through identification, development, and, ultimately, to clinical use. Therefore, laboratory medicine research, translation medical research, comprehensive preclinical studies, and most clinical studies focused on development and early phase clinical trials are all within the scope of the journal.

Scope

- Pathogenesis and mechanisms of diseases
- Cardiovascular diseases
- Biomaterial in biomedical research
- Novel targets in various therapeutic areas: cardiovascular, vascular, hematology, oncology, neurology, orthopedics, dermatology, ophthalmology
- Biomarker discovery and early diagnosis research
- Drug discovery and drug development, biomedicine, and pharmacotherapy
- Biopharmaceutical biomedicine: biologics, and biosimilars
- Nanobiotechnological advances in biomedicine: nanomedicine, nanoscaffold implants (synthetic vascular graft), biosensors, bioimaging, gene therapy, vaccine, cell therapy, and tissue engineering
- Neurobiology and clinical neuroscience
- Neuromodulation

Author Benefits

Open Access

Unlimited and free access for readers

No Copyright Constraints

Retain copyright of your work and free use of your article

Thorough Peer-Review

No Space Constraints, No Extra Space or Color Charges

No restriction on the maximum length of the papers, number of figures, or use of colors

Journal Rank

JCR - Q1 (Pharmacology and Pharmacy) /
CiteScore - Q1 (Medicine (miscellaneous))

Coverage by Leading Indexing Services

Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases

Rapid Publication

A first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025)

MDPI is a member of

CASPA



STM¹



SPARC*
Europe



DOAJ



ORCID

Affiliated Society:

Society for Regenerative Medicine (Russian Federation) (RPO)



Editorial Office

biomedicines@mdpi.com

MDPI

Grosspeteranlage 5

4052 Basel, Switzerland

Tel: +41 61 683 77 34

mdpi.com

July 2025

